Clinical Trials Browser

Phase 2 × NIH × aldesleukin × Clear all

NCT03412877 2026-04-14

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT02621021 2026-04-01

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT02133196 2026-03-24

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Phase 2 Recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis, Carcinoma, Adenosquamous

NCT01174121 2026-03-04

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Phase 2 Recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05155033 2026-02-17

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Recruiting

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT01319565 2025-12-19

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Phase 2 Completed

102 enrolled 12 charts

Melanoma, Skin Neoplasms

NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Phase 2 Withdrawn

Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04102436 2024-03-12

Non-Viral TCR Gene Therapy

Phase 2 Withdrawn

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Urogenital Neoplasms

NCT01993719 2023-01-18

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2 Completed

33 enrolled 21 charts

Melanoma

NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Phase 2 Completed

11 enrolled 12 charts

BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

NCT04536922 2021-02-01

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Phase 2 Withdrawn

Gastrointestinal

Metastatic HPV-16 Positive Squamous Cell Anal Cancer

NCT01369875 2019-12-10

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Phase 2 Terminated

2 enrolled 8 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT00670748 2019-11-19

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Phase 2 Terminated

45 enrolled 15 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT01258855 2019-05-10

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

84 enrolled 13 charts

Melanoma

NCT01814046 2018-10-11

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Phase 2 Terminated

24 enrolled 13 charts

Uveal Melanoma, Neoplasm Metastasis

NCT01585428 2018-03-07

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

Phase 2 Completed

29 enrolled 12 charts

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Papillomavirus Infections

NCT00001827 2017-10-06

p53 Vaccine for Ovarian Cancer

Phase 2 Terminated

Neoplasms, Ovarian Neoplasms

NCT02111863 2017-09-19

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2 Terminated

6 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT00089778 2017-08-01

Vaccine Treatment of Kidney Cancer

Phase 2 Terminated

11 enrolled 12 charts

Kidney Neoplasms

NCT01271907 2017-08-01

Drosophila-generated CTL

Phase 2 Terminated

3 enrolled 8 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT02062359 2016-06-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Phase 2 Terminated

2 enrolled 7 charts

Melanoma, Neoplasm Metastasis

NCT00096382 2015-10-28

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

34 enrolled 11 charts

Melanoma

NCT00610311 2015-10-28

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Phase 2 Terminated

3 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT00612222 2015-10-28

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Phase 2 Terminated

4 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT00704938 2015-10-28

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Phase 2 Terminated

3 enrolled 8 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT00706992 2015-10-28

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Phase 2 Terminated

50 enrolled 13 charts

Melanoma

NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase 2 Completed

4 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT01160445 2015-10-28

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Phase 2 Terminated

9 enrolled 9 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma

NCT00665470 2015-10-19

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

Phase 2 Completed

10 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT01495572 2015-10-15

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Phase 2 Terminated

5 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT01118091 2015-10-08

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

Phase 2 Completed

12 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT00126490 2015-06-30

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase 2 Completed

19 enrolled 9 charts

Carcinoma, Renal Cell

NCT00020254 2015-04-29

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00301990 2014-01-10

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00002845 2013-12-19

Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Unknown

Melanoma

NCT00002846 2013-12-19

Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00002847 2013-12-19

Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00080977 2013-12-19

High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00002589 2013-12-18

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003181 2013-12-04

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003090 2013-11-06

Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00003604 2013-11-06

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003664 2013-11-06

Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00006228 2013-10-08

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00005038 2013-09-20

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003743 2013-09-17

Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation

Phase 2 Unknown

Neuroblastoma

NCT00059904 2013-07-18

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse

NCT00002535 2013-06-26

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Phase 2 Completed

Melanoma

NCT00003568 2013-06-26

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019084 2013-06-20

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Phase 2 Completed

BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma